Listen on the go
Downloads

View and download resources from this activity to support your learning and share with colleagues

Download Slides
CORRECT!
Next question
Faculty & Disclosures
Dr Lizza Hendriks

Maastricht University Medical Center, Maastricht, The Netherlands

Dr Lizza Hendriks is a pulmonologist specializing in lung cancer at Maastricht University Medical Center, The Netherlands, where she leads the Clinical Lung Cancer Research Department. Her main interest is in brain metastases in patients with lung cancer, obtaining a PhD on this topic in 2016. read more

Dr Hendriks leads the Innovative Cancer Diagnostics Therapy group at the School for Oncology and Developmental Biology (GROW) at Maastricht University and is (local) principal investigator in several phase II and III clinical trials, focusing on (locally) advanced NSCLC and SCLC, targeted treatments and immunotherapies. She is an active member of Dutch (Dutch Society of Pulmonology [NVALT] and the Tuberculosis and Netherlands Respiratory Society), European (European Organisation for Research and Treatment of Cancer [EORTC], European Respiratory Society, European Society for Medical Oncology [ESMO] and the European Thoracic Oncology Platform) and global societies (American Society of Clinical Oncology and the International Association for the Study of Lung Cancer). Dr Hendriks is secretary of the NVALT studies foundation and chairs the EORTC sub-committee on Systemic Treatment for Metastatic NSCLC. She is a member of national and ESMO guideline committees and is a programme committee member or chair of several international conferences. She is a member of the Young Academy of the Royal Netherlands Academy of Arts and Sciences.

Dr Lizza Hendriks discloses: Advisory board or panel fees from Amgen, Anheart, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Lilly, Merck, MSD, Novartis, Pfizer and Takeda. Grants/research support from AbbVie, Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim (relationship terminated), Gilead, GSK, Merck, Mirati, MSD, Novartis, Pfizer, Roche Genentech and Takeda. Other financial or material support (royalties, patent, etc.) from Secretary NVALT studies foundation and Subchair EORTC metastatic NSCLC systemic therapy. Speaker’s bureau fees from AstraZeneca, Bayer, Benecke, GSK, High5 Oncology, Janssen, Lilly, MSD, Pfizer, Sanofi and Takeda.
Dr Jacob Sands

Dana-Farber Cancer Institute, Boston, MA, USA

Dr Jacob Sands is a thoracic oncologist at the Dana-Farber Cancer Institute, Boston, MA, USA, who specializes in treating lung cancer and conducts clinical and translational work in lung cancer diagnostics and treatment. read more

Dr Sands leads a National Cancer Institute-sponsored adjuvant non-small cell lung cancer (NSCLC) study with planned enrolment of >1,200 patients, is a co-author of manuscripts that have changed the SCLC paradigm, including lurbinectedin and tarlatamab, as well as a lead author and presenter of datopotamab deruxtecan for NSCLC. He is also a co-founder and president of the Rescue Lung Society, a non-profit medical society focused on advancing lung screening.

Dr Jacob Sands discloses: Consultancy fees from AbbVie, Amgen, AstraZeneca, Daiichi Sankyo, G1 Therapeutics, Guardant, Lilly, Medtronic, Merck, Pharma Mar and Sanofi (all relationships terminated).
Prof. Suresh Senan

Amsterdam University Medical Center, Amsterdam, The Netherlands

Professor Suresh Senan is a radiation oncologist at the Amsterdam University Medical Center in The Netherlands. read more

His research has focused on trials of systemic agents and radiation for lung malignancies, new radiotherapy techniques and studying population outcomes. He is a faculty member for thoracic malignancies at the European Society of Medical Oncology and the International Association for the Study of Lung Cancer.

Prof. Suresh Senan discloses: Advisory board or panel fees from AstraZeneca, BMS, MSD and Varian Medical Systems. Grants/research support from AstraZeneca.
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Lung Cancer

    An Introduction to Lung Cancer

    In some Western countries, the frequency and mortality of lung cancer are decreasing due to decades of public education and tobacco control policies, even though it still remains a major cause of mortality worldwide. Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Lung Cancer Content

    Lung Cancer, Immunotherapy
    Watch Time: 39 mins
    touchMDT
    Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors
    CE/CME ACCREDITED Dr Lizza Hendriks, Dr Jacob Sands, Prof. Suresh Senan Translations available:

    A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).

    Learning objectives
    Learning Objectives
    • Evaluate the potential role of immune checkpoint inhibitors in the treatment of patients with limited-stage small cell lung cancer
    • Recall the latest data for ICIs in LS-SCLC
    • Examine the possible impact of ICIs on the management of patients with LS-SCLC
    Lung Cancer
    Watch Time: 55 mins
    touchMDT
    Precision targeting of MET in NSCLC: A multidisciplinary approach
    CE/CME ACCREDITED Dr Xiuning Le, Dr Christine Argento, Dr Sandra Cuellar, Ms Stephanie McDonald, Prof. Albrecht Stenzinger

    A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.

    Learning objectives
    Learning Objectives
    • Recognize the importance of identifying patients with MET alterations in NSCLC and choose the most appropriate strategy to detect specific gene alterations
    • Evaluate the evidence from completed or ongoing clinical trials on the use of MET inhibitors in selected patients with advanced NSCLC and implications for future practice
    • Apply clinical trial data on MET inhibitors in NSCLC, including adverse event management, using an holistic approach to patient care
    Lung Cancer
    Watch Time: 15 mins
    touchFOCUS
    Targets in early NSCLC: A focus on EGFR-mutant treatment options
    CE/CME ACCREDITED Dr Jennifer Carlisle

    Watch an expert in lung cancer discuss the treatment options for patients with early-stage EGFR-mutant NSCLC

    Learning objectives
    Learning Objectives
    • Evaluate evidence-based targeted perioperative treatment strategies and best practices for patients with resectable EGFR-mutant NSCLC
    • Outline the clinical implications of the latest data on the role of targeted treatment approaches in patients with early unresectable EGFR-mutant NSCLC
    Lung Cancer
    Developed by Touch
    Nivolumab plus Relatlimab alongside chemotherapy demonstrated improved clinical benefit in the RELATIVITY-104 trial
    Nicolas Girard Watch Time: 6 minutes

    The phase II RELATIVITY-104 trial assessed the combination of nivolumab (NIVO) and relatlimab (RELA), a LAG-3-blocking antibody, alongside chemotherapy (PDCT) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). In this randomized trial, patients receiving NIVO + RELA + PDCT demonstrated a higher overall response rate (ORR) (51.3%) compared to NIVO + PDCT […]

    Lung Cancer
    Watch Time: 41 mins
    touchPANEL DISCUSSION
    Expanding HER2 horizons: Implications for NSCLC and beyond
    CE/CME ACCREDITED Dr Razelle Kurzrock, Dr Lyudmila Bazhenova, Dr Ignacio Wistuba Translations available:

    Two oncologists and a pathologist discuss the implications of HER2 targeting in solid tumours, with a focus on NSCLC.

    Learning objectives
    Learning Objectives
    • Evaluate the clinical implications for tissue-agnostic HER2-targeted treatments for patients with advanced cancer
    • Discuss the latest data for HER2 targeting therapies in patients with advanced NSCLC and HER2 alterations
    • Outline best practices and guidelines for biomarker testing to establish HER2 status in patients with advanced NSCLC
    Breast Cancer, Dermatological Cancers, Lung Cancer, Renal Cancer
    ESMO Congress 2024 – 13 – 17 September, Barcelona Spain

    We’re looking forward to the ESMO Congress 2024 which is taking place in Madrid between 13- 17  September, 2024. Promising attendees an opportunity to explore the latest technologies, treatments, and products in the field of oncology, we are excited to provide independent, expert video coverage of key data. You can sign up here to receive […]

    Breast Cancer, Dermatological Cancers, Gastrointestinal Cancers, Genitourinary Cancer, Gynaecological Cancers, Haematological Malignancies, Haematology, Head and Neck Cancer, Immunotherapy, Lung Cancer, Endocrine Cancers, Paediatric Oncology
    Space medicine: Can microgravity transform pharmaceutical manufacturing?

    In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

    Breast Cancer, Colorectal Cancer, Gastrointestinal Cancers, Lung Cancer
    Watch Time: 15 mins
    touchFOCUS
    Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches
    CE/CME ACCREDITED Dr Dana Chase

    Watch Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment.

    Learning objectives
    Learning Objectives
    • Discuss the implications of tumour-agnostic approaches in oncology and the role of tumour-agnostic biomarkers, such as HER2, across solid tumour types
    • Evaluate the use of HER2 as a tumour-agnostic biomarker in expanding the application of HER2-targeted therapies across various HER2-positive cancers
    Breast Cancer, Gastrointestinal Cancers, Haematological Malignancies, Lung Cancer
    Trending at #ASCO2024

    The annual ASCO2024 meeting was packed as always with the latest trial data and treatment advances in oncology.

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup